Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 885-887

  Marazzi, Giuseppe ^a   Pelliccia, Francesco ^b   Campolongo, Giuseppe ^a   Cacciotti, Luca ^c   Poggi, Sara ^b   Tanzilli, Alessandra ^b   Di Iorio, Martina ^b   Volterrani, Maurizio ^a   Lainscak, Mitja ^d   Rosano, Giuseppe M ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MG Vannini Hospital   (Italy)

^d General and Teaching Hospital Celje   (Slovenia)

Author keywords

Cardiovascular risk; Combination therapy; Hypercholesterolemia; Hypertension

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN PLUS INDAPAMIDE PLUS PERINDOPRIL; AMLODIPINE PLUS INDAPAMIDE PLUS PERINDOPRIL; ATORVASTATIN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; MIDDLE AGED; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84981173503     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.163     Document Type: Article

References (17)

1. [1] Antonakoudis, G., Poulimenos, I., Kifnidis, K., Zouras, C., Antonakoudis, H., Blood pressure control and cardiovascular risk reduction. Hippokratia 11:3 (Jul-Sep 2007), 114–119.
2. [2] Bangalore, S., Kamalakkannan, G., Parkar, S., et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120 (2007), 713–719.
3. [3] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Roccella, E.J., The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
4. [4] Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T., Mehlsen, J., Nieminen, M., O'Brien, E., Ostergren, J., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentrerandomised controlled trial. Lancet 366 (2005), 895–906.
5. [5] Gerbino, P.P., Shoheiber, O., Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am. J. Health Syst. Pharm. 64 (2007), 1279–1283.
6. [6] Gupta, A.K., Arshad, S., Poulter, N.R., Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:2 (Feb 2010), 399–407.
7. [7] Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., Velazquez, E.J., Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359 (2008), 2417–2428.
8. [8] Jamerson, K., Weber, M.A., Bakris, G.L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., EJ, V., the ACCOMPLISH Trial Investigators, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359 (2008), 2417–2428.
9. [9] Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G.T., Mitchell, L., Plat, F., Schork, A., Smith, B., Zanchetti, A., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004), 2022–2031.
10. [10] Leenen, F.H., Wilson, T.W., Bolli, P., et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. J. Cardiol. 13 (1997), 914–920.
11. [11] Lloyd-Jones, D.M., Goff, D.C., Stone, N.J., Guidelines for cardiovascular risk assessment and cholesterol treatment. JAMA, 311(21), Jun 4 2014, 2235.
12. [12] Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., StruijkerBoudier, H.A.J., Zanchetti, A., Guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28 (2007), 1462–1536.
13. [13] O'Brien, E., Atkins, N., Stergiou, G., et al. Working group on blood pressure monitoring of the European Society of Hypertension. European Society of Hypertension International Protocol Revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press. Monit. 15 (2010), 23–38.
14. [14] Palmieri, L., Rielli, R., Demattè, L., Donfrancesco, C., La Terza, G., De Sanctis, C.P., Dima, F., Lo Noce, C., Giannelli, A.M., Brignoli, O., Cuffari, A., De Rosa, M., Addis, A., Laurendi, G., Giampaoli, S., Cardiovascular risk assessment: preliminary results. G. Ital. Cardiol. (Rome) 11:2 (Feb 2010), 154–161.
15. [15] Schroeder, K., Fahey, T., Ebrahim, S., How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med. 164 (2004), 722–732.
16. [16] Shewan, L.G., Rosano, G.M.C., Henein, M.Y., Coats, A.J.S., A statement on ethical standards in publishing scientific articles in the International Journal of Cardiology family of journals. Int. J. Cardiol. 170 (2014), 253–254.
17. [17] Wald, D.S., Law, M., Morris, J.K., Bestwick, J.P., Wald, N.J., Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122:3 (Mar 2009), 290–300.